CCND1 and melanoma: Cyclin D1 could be targeted in melanoma in several ways—extensively reviewed in Yadav et al. (2015) and González-Ruiz et al. (2020)—by inhibition of chromosome band 11q13 and/or CCND1; by direct inhibition of cyclin D1; by CDK inhibition, acting upstream in melanoma-related pathways involving cyclin D1; or combining agents that act against cyclin D1 with other antitumor drugs.